These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18596910)

  • 21. A synthetic globotriaosylceramide analogue inhibits HIV-1 infection in vitro by two mechanisms.
    Harrison AL; Olsson ML; Jones RB; Ramkumar S; Sakac D; Binnington B; Henry S; Lingwood CA; Branch DR
    Glycoconj J; 2010 Jul; 27(5):515-24. PubMed ID: 20582467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease.
    Berzsenyi MD; Woollard DJ; McLean CA; Preiss S; Perreau VM; Beard MR; Scott Bowden D; Cowie BC; Li S; Mijch AM; Roberts SK
    J Hepatol; 2011 Sep; 55(3):536-544. PubMed ID: 21266183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.
    Herrera E; Gomara MJ; Mazzini S; Ragg E; Haro I
    J Phys Chem B; 2009 May; 113(20):7383-91. PubMed ID: 19402654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.
    Fernández-Vidal M; Rojo N; Herrera E; Gómara MJ; Haro I
    Biophys Chem; 2008 Jan; 132(1):55-63. PubMed ID: 17988786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1.
    Dettin M; Pasquato A; Scarinci C; Zanchetta M; De Rossi A; Di Bello C
    J Med Chem; 2004 Jun; 47(12):3058-64. PubMed ID: 15163187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What you need to know about GB virus C.
    George SL; Varmaz D
    Curr Gastroenterol Rep; 2005 Feb; 7(1):54-62. PubMed ID: 15701300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.
    Koedel Y; Eissmann K; Wend H; Fleckenstein B; Reil H
    J Virol; 2011 Jul; 85(14):7037-47. PubMed ID: 21543477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection.
    Gómara MJ; Fernández L; Pérez T; Ercilla G; Haro I
    Anal Biochem; 2010 Jan; 396(1):51-8. PubMed ID: 19751699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART.
    Björkman P; Flamholc L; Molnegren V; Marshall A; Güner N; Widell A
    AIDS; 2007 Jul; 21(12):1641-3. PubMed ID: 17630561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effect of GB virus C co-infection in Human Immunodeficiency Virus type 1-infected individuals.
    Hattori J; Okumura N; Yamazaki Y; Uchiyama M; Hamaguchi M; Nishiyama Y; Kaneda T
    Microbiol Immunol; 2007; 51(2):193-200. PubMed ID: 17310087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
    Joshi P; Prasad VR
    J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
    Galatola R; Vasconcelos A; Pérez Y; Cruz A; Pujol M; Alsina MA; Gómara MJ; Haro I
    Eur J Med Chem; 2014 Oct; 86():589-604. PubMed ID: 25218908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of HIV-2(ROD) replication in a lymphoblastoid cell line by the alpha1-antitrypsin Portland variant (alpha1-PDX) and the decRVKRcmk peptide: comparison with HIV-1(LAI).
    Bahbouhi B; Bendjennat M; Chiva C; Kogan M; Albericio F; Giralt E; Seidah NG; Bahraoui E
    Microbes Infect; 2001 Nov; 3(13):1073-84. PubMed ID: 11709287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GB virus-C infection in patients infected with the human immunodeficiency virus.
    Tillmann HL; Manns MP
    Antiviral Res; 2001 Nov; 52(2):83-90. PubMed ID: 11672817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy.
    Kato T; Mizokami M; Orito E; Ohba K; Nakano T; Kondo Y; Tanaka Y; Ueda R; Mukaide M; Yasuda K; Iino S
    J Med Virol; 1999 Apr; 57(4):376-82. PubMed ID: 10089050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
    Gómara MJ; Sánchez-Merino V; Paús A; Merino-Mansilla A; Gatell JM; Yuste E; Haro I
    Biochim Biophys Acta; 2016 Jun; 1860(6):1139-48. PubMed ID: 26905802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 and GBV-C co-infection in Venezuela.
    Rodríguez AK; Garzaro DJ; Loureiro CL; Gutiérrez CR; Ameli G; Jaspe RC; Porto L; Monsalve F; Pozada Á; Vázquez L; Quiñones-Mateu ME; Pujol FH; Rangel HR
    J Infect Dev Ctries; 2014 Jul; 8(7):863-8. PubMed ID: 25022296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.
    Souza IE; Allen JB; Xiang J; Klinzman D; Diaz R; Zhang S; Chaloner K; Zdunek D; Hess G; Williams CF; Benning L; Stapleton JT
    J Clin Microbiol; 2006 Sep; 44(9):3105-13. PubMed ID: 16954234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative analysis of the substrate permissiveness of HCV and GBV-B NS3/4A proteases reveals genetic evidence for an interaction with NS4B protein during genome replication.
    Benureau Y; Warter L; Malcolm BA; Martin A
    Virology; 2010 Oct; 406(2):228-40. PubMed ID: 20701941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein.
    Jin H; Li D; Sivakumaran H; Lor M; Rustanti L; Cloonan N; Wani S; Harrich D
    mBio; 2016 Jul; 7(4):. PubMed ID: 27381288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.